Issue 2/2017
Content (10 Articles)
Emergent Challenges in Determining Costs for Economic Evaluations
Josephine C. Jacobs, Paul G. Barnett
Systematic Review of the Cost Effectiveness of Insulin Analogues in Type 1 and Type 2 Diabetes Mellitus
Asrul Akmal Shafie, Chin Hui Ng, Yui Ping Tan, Nathorn Chaiyakunapruk
Economic Evaluations of Pharmaceuticals Granted a Marketing Authorisation Without the Results of Randomised Trials: A Systematic Review and Taxonomy
Anthony J. Hatswell, Nick Freemantle, Gianluca Baio
Pharmacoeconomic Considerations in Treating Actinic Keratosis: An Update
Spencer M. Vale, Dane Hill, Steven R. Feldman
Abiraterone Acetate for the Treatment of Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: An Evidence Review Group Perspective of an NICE Single Technology Appraisal
Bram L. T. Ramaekers, Rob Riemsma, Florian Tomini, Thea van Asselt, Sohan Deshpande, Steven Duffy, Nigel Armstrong, Johan L. Severens, Jos Kleijnen, Manuela A. Joore
A Review of Ruxolitinib for the Treatment of Myelofibrosis: A Critique of the Evidence
Ros Wade, Robert Hodgson, Mousumi Biswas, Melissa Harden, Nerys Woolacott
A Review of US Drug Costs Relevant to Medicare, Medicaid, and Commercial Insurers Post-Affordable Care Act Enactment, 2010–2016
Jacquelyn McRae, F. Randy Vogenberg, Silky Webb Beaty, Elizabeth Mearns, Stefan Varga, Laura Pizzi
Cost Effectiveness of Naloxegol for Opioid-Induced Constipation in the UK
Richard Lawson, James Ryan, Frederic King, Jo Wern Goh, Eszter Tichy, Kevin Marsh
Simulation Modelling in Ophthalmology: Application to Cost Effectiveness of Ranibizumab and Aflibercept for the Treatment of Wet Age-Related Macular Degeneration in the United Kingdom
Lindsay Claxton, Robert Hodgson, Matthew Taylor, Bill Malcolm, Ruth Pulikottil Jacob
Economic Evaluation in Duchenne Muscular Dystrophy: Model Frameworks for Cost-Effectiveness Analysis
Erik Landfeldt, Lars Alfredsson, Volker Straub, Hanns Lochmüller, Katharine Bushby, Peter Lindgren